Certara

Update in progress

CERT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryHealth Information Services

Certara, Inc. and its subsidiaries deliver technology-driven services and software for biosimulation across drug discovery, preclinical and clinical research, regulatory submissions, and market access worldwide. Their offerings include model-informed drug development; PK/PD simulations; Simcyp PBPK and translational platforms; Phoenix, Pirana, and Chemaxon chemistry tools; D360 informatics; Pinnacle 21 data standards and submissions; and CoAuthor/GlobalSubmit for submissions and publications.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.07; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive